PMID- 16601438
OWN - NLM
STAT- MEDLINE
DCOM- 20060418
LR  - 20151119
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Linking)
VI  - 29
IP  - 2
DP  - 2006 Apr
TI  - Evaluation of HER-2/neu amplification and other biological markers as predictors 
      of response to neoadjuvant anthracycline-based chemotherapy in primary breast 
      cancer: the role of anthracycline dose intensity.
PG  - 171-7
AB  - OBJECTIVES: The value of HER-2/neu status as a predictor of response to 
      anthracycline-based chemotherapy is still a matter of debate. We evaluated the 
      contribution of HER-2/neu gene amplification and other biologic markers in 
      predicting response to different doses of neoadjuvant anthracycline-based 
      chemotherapy. METHODS: Clinical and pathologic records of 115 primary breast 
      cancer patients were reviewed. Forty-eight and 67 patients received high 
      (doxorubicin > or =20 mg/m2/wk; epirubicin > or =30 mg/m2/wk) and moderate-low 
      anthracycline dose intensity regimens, respectively. Pathologic diagnosis, 
      hormonal receptor status (HR), Ki67, and HER-2/neu status were assessed on tumor 
      samples before neoadjuvant chemotherapy. HER-2/neu was determined by fluorescence 
      in situ hybridization (FISH). RESULTS: HER-2/neu amplification was observed in 
      29/115 (25%) tumors, 18 from moderate-low-dose and 11 from high-dose group. In 
      the univariate analysis, a high Ki67 index (> or =20%) and positive clinical 
      axillary nodes were predictive of an objective tumor response (P = 0.033 and 
      0.001, respectively). In the multivariate analysis, Ki67 was the only factor 
      predictive of response (OR = 3.08, 95% CI = 1.1-8.5, P = 0.03). HER-2/neu status 
      was not a factor in predicting objective response to different anthracycline dose 
      intensities. The same finding was observed with regards to HR and Ki67. 
      CONCLUSIONS: In our series, no significant dose-response relationship was found 
      according to HER-2/neu status.
FAU - Bozzetti, Cecilia
AU  - Bozzetti C
AD  - Deparment of Medical Oncology, University Hospital, Parma, Italy. 
      cbozzetti@ao.pr.it
FAU - Musolino, Antonino
AU  - Musolino A
FAU - Camisa, Roberta
AU  - Camisa R
FAU - Bisagni, Giancarlo
AU  - Bisagni G
FAU - Flora, Marcella
AU  - Flora M
FAU - Bassano, Cristina
AU  - Bassano C
FAU - Martella, Eugenia
AU  - Martella E
FAU - Lagrasta, Costanza
AU  - Lagrasta C
FAU - Nizzoli, Rita
AU  - Nizzoli R
FAU - Personeni, Nicola
AU  - Personeni N
FAU - Leonardi, Francesco
AU  - Leonardi F
FAU - Cocconi, Giorgio
AU  - Cocconi G
FAU - Ardizzoni, Andrea
AU  - Ardizzoni A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
RN  - 0 (Anthracyclines)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anthracyclines/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*drug therapy/*genetics/surgery
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Ki-67 Antigen
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoadjuvant Therapy
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2006/04/08 09:00
MHDA- 2006/04/19 09:00
CRDT- 2006/04/08 09:00
PHST- 2006/04/08 09:00 [pubmed]
PHST- 2006/04/19 09:00 [medline]
PHST- 2006/04/08 09:00 [entrez]
AID - 00000421-200604000-00014 [pii]
AID - 10.1097/01.coc.0000204405.96572.f9 [doi]
PST - ppublish
SO  - Am J Clin Oncol. 2006 Apr;29(2):171-7. doi: 10.1097/01.coc.0000204405.96572.f9.